drugset / Trial / NCT04484506
Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma
Phase 2
Unknown
150 enrolled
Peking University
Hebei Medical University Fourth Hospital · collabJiangxi Provincial Cancer Hospital · collabPeking University Cancer Hospital & Institute · collabPeking University International Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The optimal first-line treatment for extra-nodal NK/T-cell lymphoma (ENKTL) has not been well-defined. This phase II study aimed to evaluate the efficacy and safety of pegaspargase, cyclophosphamide, vincristine, etoposide and prednisone (COEPL) regimen combined with radiotherapy for patients with newly diagnosed ENKTL.
Timeline
- Start
- 2011-10-20
- Primary completion
- 2023-12-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 750 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Pegaspargase | Protein / enzyme biologic | 2500 iu | Intramuscular |
| Subject | Prednisone | Other / unclassified | 100 mg | Oral |
| Subject | Vincristine | Small molecule | 1.4 mg/m2 | Intravenous |